Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

17828

Shown on this page

Current sort

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Interventions: CPAP; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 116
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more

Conditions: Severe Alopecia Areata
Interventions: Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more

Conditions: Parkinson's Disease
Interventions: BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo; Drug
Lead sponsor: Bial R&D Investments, S.A.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Sotorasib, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 27
States / cities: Santa Barbara, California • Newark, Delaware • Coral Springs, Florida + 23 more

Conditions: Liver Diseases
Interventions: Transitional Liver Clinic (TLC); Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more

Conditions: Breast Cancer
Interventions: Abemaciclib; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 3
States / cities: Chicago, Illinois • Iowa City, Iowa • Columbus, Ohio

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 62
States / cities: Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 50 more

Conditions: Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Interventions: OnabotulinumtoxinA; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Tricuspid Regurgitation (TR)
Interventions: Tricuspid Transcatheter Edge-to-Edge Repair (TEER); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 8
States / cities: Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 5 more

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole; Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 21
States / cities: Orange, California • Sacramento, California • Stanford, California + 16 more

Conditions: Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver, Benign Liver Tumor
Interventions: HistoSonics Edison System; Device
Lead sponsor: HistoSonics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 35
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 28 more

Conditions: Hypertension
Interventions: Core intervention (Fitbit tracking and BP health education), Aerobic training (AT), Dynamic resistance training (DRT), Isometric resistance training (IRT); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 44 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Clinical trials in Chicago, Illinois

Filter and sort this location

Institutions in Chicago

Live official records

Sleep for Stroke Management and Recovery Trial

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

A Post-Market Assessment of the Safety and Performance of the TriClip™ System

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

A MOST Framework Trial Evaluating the MOst effectiVe Exercise Types for Blood Pressure Control